CAR-T cells specifically bind to the target antigens (such as CD19, BCMA and CLL1 expressed on tumor cells) on the surface of cancer cells through the antigen-binding region of the CAR, thereby achieving targeted killing of tumor cells (3). This evidence concerns the gene TNFRSF17 and neoplasm.